Our current work thus provides an important cue to develop a therapeutic strategy for cancers with FEN1, POL δ and LIG1 mutations in which Okazaki fragment joining is strongly suppressed upon treatment with PARP and HDAC inhibitors (63). This evidence concerns the gene HDAC9 and cancer.